Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV

Udofia et al., Network Modeling Analysis in Health Informatics and Bioinformatics, doi:10.1007/s13721-021-00299-2
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19ivm.org
In Silico analysis finding that ivermectin had the highest binding energy against the 3CLpro of SARS-CoV-2 and RdRps of both SARS-CoV and SARS-CoV-2.
Ivermectin, better known for antiparasitic activity, is a broad spectrum antiviral with activity against many viruses including H7N7 Götz, Dengue Tay, Wagstaff, HIV-1 Wagstaff, Simian virus 40 Wagstaff (B), Zika Barrows, Yang, West Nile Yang, Yellow Fever Mastrangelo, Varghese, Japanese encephalitis Mastrangelo, Chikungunya Varghese, Semliki Forest virus Varghese, Human papillomavirus Li, Epstein-Barr Li, BK Polyomavirus Bennett, and Sindbis virus Varghese.
Ivermectin inhibits importin-α/β-dependent nuclear import of viral proteins Götz, Kosyna, Wagstaff, Wagstaff (B), inhibits SARS-CoV-2 3CLpro Mody, shows spike-ACE2 disruption at 1nM with microfluidic diffusional sizing Fauquet, binds to glycan sites on the SARS-CoV-2 spike protein preventing interaction with blood and epithelial cells and inhibiting hemagglutination Boschi, Scheim, exhibits dose-dependent inhibition of lung injury Abd-Elmawla, Ma, may inhibit SARS-CoV-2 induced formation of fibrin clots resistant to degradation Vottero, may be beneficial for COVID-19 ARDS by blocking GSDMD and NET formation Liu (C), shows protection against inflammation, cytokine storm, and mortality in an LPS mouse model sharing key pathological features of severe COVID-19 DiNicolantonio, Zhang, may be beneficial in severe COVID-19 by binding IGF1 to inhibit the promotion of inflammation, fibrosis, and cell proliferation that leads to lung damage Zhao, may minimize SARS-CoV-2 induced cardiac damage Liu, Liu (B), increases Bifidobacterium which plays a key role in the immune system Hazan, has immunomodulatory Munson and anti-inflammatory DiNicolantonio (B), Yan properties, and has an extensive and very positive safety profile Descotes.
Udofia et al., 25 Mar 2021, peer-reviewed, 5 authors.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperIvermectinAll
In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV
Inemesit A Udofia, Kofoworola O Gbayo, Oluwakemi A Oloba-Whenu, Taofeek B Ogunbayo, Chukwuemeka Isanbor
Network Modeling Analysis in Health Informatics and Bioinformatics, doi:10.1007/s13721-021-00299-2
An outbreak of a cluster of viral pneumonia cases, subsequently identified as coronavirus disease 2019 , due to a novel SARS-CoV-2 necessitates an urgent need for a vaccine to prevent infection or an approved medication for a cure. In our in silico molecular docking study, a total of 173 compounds, including FDA-approved antiviral drugs, with good ADME descriptors, and some other nucleotide analogues were screened. The results show that these compounds demonstrate strong binding affinity for the residues at the active sites of RNA-dependent RNA-polymerase (RdRp) modelled structures and Chymotrypsin-like cysteine protease (3CLpro) of the HCoV proteins. Free energies (ΔG's) of binding for SARS-CoV-2 and SARS-CoV RdRp range from -5.4 to -8.8 kcal/mol and -4.9 to -8.7 kcal/mol, respectively. Also, SARS-CoV-2 and SARS-CoV 3CLpro gave ΔG values ranging from − 5.1 to − 8.4 kcal/mol and − 5.5 to − 8.6 kcal/mol, respectively. Interesting results are obtained for ivermectin, an antiparasitic agent with broad spectrum activity, which gave the highest binding energy value (− 8.8 kcal/mol) against the 3CLpro of SARS-CoV-2 and RdRps of both SARS-CoV and SARS-CoV-2. The reason for such high binding energy values is probably due to the presence of hydroxy, methoxy and sugar moieties in its structure. The stability of the protein-ligand complexes of polymerase inhibitors considered in this investigation, such as Sofosbuvir, Remdesivir, Tenofovir, Ribavirin, Galidesivir, 5c3, 5h1 and 7a1, show strong to moderate hydrogen bonding and hydrophobic interactions (π-π stacked, π-π T-shaped, π-sigma and π-alkyl). The stability provided from such interactions translate into greater antiviral activity or inhibitory effect of the ligands. Assessment of the average free energies of binding of the FDA approved drugs are highly comparable for conformers of a particular inhibitor, indicating similar modes of binding within the pockets.
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s13721-021-00299-2.
References
Andersen, Rambaut, Lipkin, Holmes, Garry, The proximal origin of SARS-CoV-2, Nat Med, doi:10.1038/s41591-020-0820-9
Bajji, Davis, Synthesis and biophysical characterization of tRNALys,3 anticodon stem-loop RNAs containing the mcm5s2U nucleoside, Org Lett, doi:10.1021/ol006605h
Beg, Shivangi, Meena, Structural Prediction and mutational analysis of Rv3906c gene of Mycobacterium tuberculosis H 37 Rv to determine its essentiality in survival, Adv Bioinform, doi:10.1155/2018/6152014
Ben-Zvi, Kivity, Langevitz, Shoenfeld, Hydroxychloroquine: from malaria to autoimmunity, Clin Rev Allergy Immunol
Biasini, Bienert, Waterhouse, Arnold, Studer et al., SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information, Nucleic Acids Res, doi:10.1093/nar/gku340
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir Res, doi:10.1016/j.antiviral.2020.104787
Cao, Xiao, Cao, Li, Kumaki et al., Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir, Antiviral Chem Chemother, doi:10.3851/IMP2672
Chaccour, Hammann, Ramón-García, Rabinovich, Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency, Am J Trop Med Hygiene, doi:10.4269/ajtmh.20-0271
Chan, Chan, Tracing the SARS-coronavirus, J Thorac Dis, doi:10.3978/j.issn.2072-1439.2013.06.19
Chen, Yiu, Wong, Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates, F1000Research, doi:10.12688/f1000research.22457.1
Cheng, Zhang, Xie, Jiang, Arnold et al., Expression, purification, and characterization of SARS coronavirus RNA polymerase, Virology, doi:10.1016/j.virol.2005.02.017
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105932
Corman, Muth, Niemeyer, Drosten, Hosts and sources of endemic human coronaviruses, Advances in virus research, doi:10.1016/bs.aivir.2018.01.001
Dallakyan, Olson, Small-molecule library screening by docking with PyRx BT-chemical biology: methods and protocols, doi:10.1007/978-1-4939-2269-7_19
Erion, Bullough, Lin, Hong, HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver, Curr Opin Investig Drugs
Fantini, Scala, Chahinian, Yahi, Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105960
Flierl, Nero, Lim, Arthur, Yao et al., Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators, J Exp Med, doi:10.1084/jem.20140391
Fox, Dixon, Guarrasi, Krubel, Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study, Lupus
Fu, Li, Zhang, Strong orbital Interaction in pi-pi Stacking System
Gao, Gao, Yan, Huang, Liu et al., Structure of the RNA-dependent RNA polymerase from COVID-19 virus, Science
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Hasan, Hossain, Analysis of COVID-19 M protein for possible clues regarding virion stability , longevity and spreading, doi:10.31219/osf.io/e7jkc
Henderleiter, Smart, Anderson, Elian, How do organic chemistry students understand and apply hydrogen bonding?, J Chem Educ, doi:10.1021/ed078p1126
Huang, Bosch, Li, Li, Kyoung et al., SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells, J Biol Chem, doi:10.1074/jbc.M508381200
Jeffrey, An introduction to hydrogen bonding
Jin, Du, Xu, Deng, Liu et al., Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors, Nature, doi:10.1038/s41586-020-2223-y
Ju, Kumar, Li, Jockusch, Russo, Nucleotide analogues as inhibitors of viral polymerases, BioRxiv, doi:10.1101/2020.01.30.927574
Ju, Li, Kumar, Jockusch, Chien et al., Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase, BioRxiv, doi:10.1101/2020.03.12.989186
Khan, Zia, Ashraf, Uddin, Ul-Haq, Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach, J Biomol Struct Dyn, doi:10.1080/07391102.2020.1751298
Kirchdoerfer, Ward, Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors, Nat Commun, doi:10.1038/s41467-019-10280-3
Lee, Yang, Parr, Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density, Phys Rev B, doi:10.1103/PhysRevB.37.785
Li, Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat Rev Drug Discov, doi:10.1038/d41573-020-00016-0
Li, Moore, Vasilieva, Sui, Wong et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature, doi:10.1038/nature02145
Lüthy, Bowie, Eisenberg, Assessment of protein models with three-dimensional profiles, Nature, doi:10.1038/356083a0
Martin, Canard, Decroly, Filovirus proteins for antiviral drug discovery: Structure/function bases of the replication cycle, Antivir Res, doi:10.1016/j.antiviral.2017.02.004
Martinez, Iverson, Rethinking the term "pi-stacking, Chem Sci, doi:10.1039/C2SC20045G
Masters, The molecular biology of coronaviruses, Adv Virus Res, doi:10.1016/S0065-3527(06)66005-3
Pamidighantam, Nakandala, Abeysinghe, Wimalasena, Yodage et al., Community science exemplars in SEAGrid science gateway: apache airavata based implementation of advanced infrastructure, Proc Comput Sci, doi:10.1016/j.procs.2016.05.535
Panigrahi, Strong and weak hydrogen bonds in proteinligand complexes of kinases: a comparative study, Amino Acids, doi:10.1007/s00726-007-0015-4
Patil, Balasubramanian, Masand, Chapter 14-dengue virus polymerase: a crucial target for antiviral drug discovery, doi:10.1016/B978-0-12-815422-9.00014-0
Pearson, Using the FASTA program to search protein and DNA sequence databases, doi:10.1385/0-89603-246-9:307
Pettersen, Goddard, Huang, Couch, Greenblatt et al., UCSF Chimera-a visualization system for exploratory research and analysis, J Comput Chem
Prabakaran, Xiao, Dimitrov, A model of the ACE2 structure and function as a SARS-CoV receptor, Biochem Biophys Res Commun, doi:10.1016/j.bbrc.2003.12.081
Raha, Merz, Chapter 9 Calculating binding free energy in protein-ligand interaction, Annual reports in computational chemistry, doi:10.1016/S1574-1400(05)01009-1
Shi, Sivaraman, Song, Mechanism for controlling the dimermonomer switch and coupling dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease, J Virol, doi:10.1128/JVI.02680-07
Solowiej, Thomson, Ryan, Luo, He et al., Steady-State and pre-steady-state kinetic evaluation of severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro Cysteine protease: development of an ion-pair model for catalysis, Biochemistry, doi:10.1021/bi702107v
Spaan, Cavanagh, Horzinek, Coronaviruses: structure and genome expression, J Gen Virol, doi:10.1099/0022-1317-69-12-2939
Spiwok, CH/π Interactions in Carbohydrate Recognition, Molecules, doi:10.3390/molecules22071038
Tomar, Mudgal, Pareek, Chapter 3-RNA-dependent RNA polymerase of alphaviruses: a potential target for the design of drugs against alphaviruses, doi:10.1016/B978-0-12-815422-9.00003-6
Touret, De Lamballerie, Of chloroquine and COVID-19, Antivir Res, doi:10.1016/j.antiviral.2020.104762
Trott, Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J Comput Chem, doi:10.1002/jcc.21334
Van Doremalen, Bushmaker, Morris, Holbrook, Gamble et al., Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1, N Engl J Med, doi:10.1056/NEJMc2004973
Walls, Park, Tortorici, Wall, Mcguire et al., Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell, doi:10.1016/j.cell.2020.02.058
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wang, Lai, Wang, Further development and validation of empirical scoring functions for structure-based binding affinity 22 Page 12 of 12 prediction, J Comput Aided Mol Des, doi:10.1023/A:1016357811882
Wang, Wang, Chen, Qin, Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures, J Med Virol, doi:10.1002/jmv.25748
Waterhouse, Bertoni, Bienert, Studer, Tauriello et al., SWISS-MODEL: homology modelling of protein structures and complexes, Nucleic Acids Res, doi:10.1093/nar/gky427
Who, Coronavirus disease (COVID, doi:10.1093/nar/gkz966
Williams, Headd, Moriarty, Prisant, Videau et al., MolProbity: More and better reference data for improved all-atom structure validation, Protein Sci, doi:10.1002/pro.3330
Yang, Roy, Zhang, Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment, Bioinformatics, doi:10.1093/bioinformatics/btt447
Yang, Yang, Ding, Liu, Lou et al., The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor, Proc Natl Acad Sci
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit